IXCHIQ Chikungunya vaccine: UK marketing authorisation withdrawn following safety review

The Medicines and Healthcare products Regulatory Agency (MHRA) has published a drug safety update for the IXCHIQ Chikungunya vaccine. Following advice from the Commission on Human Medicines (CHM), the MHRA has concluded that the benefit-risk balance for the IXCHIQ chikungunya vaccine is no longer considered favourable and the UK marketing authorisation has been withdrawn.

Healthcare professionals must no longer prescribe, supply or administer the IXCHIQ vaccine and should dispose of any remaining stock in accordance with local policies.

Further information and advice can be found on the MHRA website.